Skip to main content

Xention to Study Biomarkers for AF Network

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Xention will study biomarkers to support the European Network for Translational Research in Atrial Fibrillation (EUTRAF), which has received a €12 million ($16.7 million) grant from the European Union to research this disorder, the company said today.

Under the agreement, Cambridge, UK-based Xention will characterize molecular biomarkers of abnormal function of ion channels linked to atrial fibrillation. It also will validate new ion channels for their therapeutic potential and will identify pharmacological tools for validating such channels.

EUTRAF is a consortium of universities and biotechnology and pharmaceutical firms around Europe that have joined together in a five-year AF study with the aim of improving diagnosis, prevention, and treatment for the disease, which affects around 6 million Europeans, or around one to two percent of the population.

The company said that AF increases the risk of stroke five-fold and it is responsible for one in five strokes, with many of these being fatal or crippling.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.